COVID-19 Vaccine Associated Anaphylaxis

Peer-Reviewed Scientific papers regarding COVID-19 Vaccine Associated Anaphylaxis

COVID-19 vaccine-associated anaphylaxis: a statement from the Anaphylaxis Committee of the World Allergy Organization

Allergic reactions, including anaphylaxis, after receiving the first dose of the Pfizer-BioNTech COVID-19 vaccine

Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14-23, 2020

Allergic reactions, including anaphylaxis, after receiving first dose of Modern COVID-19 vaccine – United States, December 21, 2020-January 10, 2021

Reports of anaphylaxis after coronavirus disease vaccination 2019, South Korea, February 26-April 30, 2021

Reports of anaphylaxis after receiving COVID-19 mRNA vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021

Immunization practices and risk of anaphylaxis: a current, comprehensive update of COVID-19 vaccination data

Relationship between pre-existing allergies and anaphylactic reactions following administration of COVID-19 mRNA vaccine

Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research

Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines

Cumulative adverse event report of anaphylaxis following injections of COVID-19 mRNA vaccine (Pfizer-BioNTech) in Japan: the first month report

COVID-19 vaccines increase the risk of anaphylaxis

Biphasic anaphylaxis after exposure to the first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19

Polyethylene glycol (PEG) is a cause of anaphylaxis to Pfizer / BioNTech mRNA COVID-19 vaccine

Elevated rates of anaphylaxis after vaccination with Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers; a secondary analysis of initial post-approval safety data

IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to COVID-19 mRNA vaccines

Anaphylactic reactions to COVID-19 mRNA vaccines: a call for further study

Anaphylaxis following Covid-19 vaccine in a patient with cholinergic urticaria

Anaphylaxis induced by CoronaVac COVID-19 vaccine: clinical features and results of revaccination.

Anaphylaxis after Modern COVID-19 vaccine

Sex differences in the incidence of anaphylaxis to LNP-mRNA vaccines COVID-19

Allergic reactions, including anaphylaxis, after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14 to 23, 2020

Allergic reactions, including anaphylaxis, after receiving the first dose of Modern COVID-19 vaccine – United States, December 21, 2020 to January 10, 2021

Prolonged anaphylaxis to Pfizer 2019 coronavirus disease vaccine: a case report and mechanism of action

Anaphylaxis reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis following vaccination with Pfizer BNT162b2

Biphasic anaphylaxis after first dose of 2019 messenger RNA coronavirus disease vaccine with positive polysorbate 80 skin test result

Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19

Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine COVID-19

Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan

Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States

Back to top